Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Expert Opinion on Therapeutic Targets|December 8, 2006
The Src signaling pathway: a potential target in melanoma and other malignanciesJade Homsi, Christopher Cubitt, Adil Daud
Expert Opinion on Pharmacotherapy|September 3, 2015
Future of combination therapy with dabrafenib and trametinib in metastatic melanomaYasaman Zia, Lawrence Chen, Adil Daud
Seminars in Cutaneous Medicine and Surgery|May 30, 2012
Cutting edge in medical management of cutaneous oncologyKim Chong, Adil Daud, Susana Ortiz-Urda, et al.
Journal of Hematology & Oncology|January 6, 2017
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patientsAdil Daud, Japinder Gill, Sheily Kamra, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2005
Cutaneous melanoma: prognostic factorsJade Homsi, Mohammed Kashani-Sabet, Jane L Messina, et al.
JCO Precision Oncology|January 7, 2022
Response to PD-1 Immunotherapy in Metastatic SpiradenocarcinomaClinton Wu, Melissa Chow, Michelle Temby, et al.
JAAD Case Reports|April 7, 2016
Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literatureGiorgia L Garrett, Steven Y He, Nica Sabouni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 19, 2019
PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell ChangeKaty K Tsai, Neharika Khurana, Timothy McCalmont, et al.
Frontiers in Medicine|January 12, 2019
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin CancerJennifer A Bridge, James C Lee, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma modelLoree Heller, Kathleen Merkler, Jeffrey Westover, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Expert Opinion on Therapeutic Targets|December 8, 2006
The Src signaling pathway: a potential target in melanoma and other malignanciesJade Homsi, Christopher Cubitt, Adil Daud
Expert Opinion on Pharmacotherapy|September 3, 2015
Future of combination therapy with dabrafenib and trametinib in metastatic melanomaYasaman Zia, Lawrence Chen, Adil Daud
Seminars in Cutaneous Medicine and Surgery|May 30, 2012
Cutting edge in medical management of cutaneous oncologyKim Chong, Adil Daud, Susana Ortiz-Urda, et al.
Journal of Hematology & Oncology|January 6, 2017
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patientsAdil Daud, Japinder Gill, Sheily Kamra, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2005
Cutaneous melanoma: prognostic factorsJade Homsi, Mohammed Kashani-Sabet, Jane L Messina, et al.
JCO Precision Oncology|January 7, 2022
Response to PD-1 Immunotherapy in Metastatic SpiradenocarcinomaClinton Wu, Melissa Chow, Michelle Temby, et al.
JAAD Case Reports|April 7, 2016
Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literatureGiorgia L Garrett, Steven Y He, Nica Sabouni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 19, 2019
PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell ChangeKaty K Tsai, Neharika Khurana, Timothy McCalmont, et al.
Frontiers in Medicine|January 12, 2019
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin CancerJennifer A Bridge, James C Lee, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma modelLoree Heller, Kathleen Merkler, Jeffrey Westover, et al.
Pageof 11